Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

BIO Reveals Program for 2013 BIO Convention in China



  BIO Reveals Program for 2013 BIO Convention in China

 3^rd Annual BIO China Will Provide Global Look at Innovation and Investment
                            Opportunities in China

BIO Convention in China 2013 BIO Convention in China 2013:Biotechnology
Industry Organization (BIO)

Business Wire

WASHINGTON -- October 31, 2013

The Biotechnology Industry Organization (BIO) today announced panel sessions
for the 3^rd annual BIO Convention in China to be held November 11-13, 2013 in
Beijing. The program will feature science-focused sessions such as vaccine
development, China’s unmet medical needs and the research and development of
orphan drugs to treat rare diseases in China, as well as business-focused
sessions exploring China’s private health care industry, early-stage VC
funding in China, and partnering models between Chinese and Western companies.
Convention programming and exhibition will take place November 12-13.

“China has the potential to build a world-class innovative biologics sector,"
said Joseph Damond, senior vice president of international affairs at
BIO. “This year’s BIO China program helps support that ambition by bringing
together western and Chinese life sciences companies as well as business
leaders, government officials and other industry representatives for learning
and deal-making opportunities.”

Three can’t miss panels include:

  * Company Partnerships in Vaccine Developments in China
    China and its neighboring countries represent a significant private sector
    opportunity for new vaccines. Chinese vaccine companies, working in
    partnership with other vaccine companies, are developing important
    medicine that addresses the specific unmet medical needs in China and
    other Asian markets. These collaborations bring novel vaccine technology
    into the Chinese research institutions while offering small and large
    Western vaccine companies the opportunity to bring new products to the
    growing Chinese private sector. Vaccines that protect against pneumococcal
    disease, HPV, influenza and RSV are in development or clinical trials. The
    panelists for this topic will discuss successful partnerships designed to
    solve key public health issues in China and other emerging markets.

    Tuesday, November 12, 11:00 a.m. – 11:55 a.m.
    Moderator: Ralf Altmeyer, PhD, Director General, Institut Pasteur of
    Shanghai, Chinese Academy of Sciences
    Panelists: Li Shi, CEO, Shanghai Zerun Biotech; Jean-Denis Shu, MD,
    Medical Director, Sanofi Pasteur, China

  * Rare Diseases in China
    The establishment of China’s first national organization against rare
    diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms
    the country’s commitment to innovative health care research. China is
    actively promoting the regulation of rare diseases and orphan drugs. This
    panel will focus on the research and development of orphan drugs in China.

    Tuesday, November 12, 1:30 p.m. – 2:25 p.m.
    Moderator: Kewen Jin, Managing Director, Nimbus Innoworks
    Panelists: Rachel Lee, China Country President, Shire; Ko-Chung Lin, PhD,
    Founder & CEO, Pharmaessentia; Jerry Zeldis, PhD, Chief Executive Officer,
    Celgene Global Health and Chief Medical Officer, Celgene Corporation

  * Dissecting China’s Unmet Medical Needs
    The prevalence of cancer, diabetes and cardiovascular diseases continue to
    rise in China, primarily due to a growing aging population and
    urbanization. To what extent are current standards of care falling short,
    and what novel products and technologies are around the corner to fill the
    void? Hear leading experts discuss these questions, and learn how the
    industry is addressing unmet medical needs to improve healthcare in China.

    Wednesday, November 13, 1:00 p.m. – 1:55 p.m.
    Moderator: Nick Zhang, PhD, China General Manager, Senior Vice President,
    Frontage Lab
    Panelists: Friedhelm Blobel, PhD, President & CEO, SciClone
    Pharmaceuticals; Bruno Osterwalder, MD, Senior VP, Senior Strategic
    Advisor Oncology, Global Drug Development and Medical, Merck Serono;
    Russell Wilson, Senior Vice President, Business Development, Novavax;
    Grace Xu, VP, Product Development & Strategic Planning, Bristol-Myers
    Squibb

Other BIO China sessions include:

  * Roadmap to Cultivate Innovative Biologics Industry in China
    The bio-industry has been designated as one of China’s seven strategic
    emerging industries (SEI) by the government. Within the bio-industry,
    therapeutic biologics hold significant promise for China to achieve
    breakthrough innovation and to address largely unmet medical needs in many
    disease areas. Today, China’s therapeutic biologics industry stands at RMB
    18 billion, representing less than 2 percent of the global total. This
    panel will explore the steps that may be taken by the government and
    industry to develop a world-class innovative biologics sector in China.

  * State of Capital Markets in US
    With capital markets opening up, 2013 saw 39 (and counting) new biotech
    IPOs – many of which are staying strong even after their initial debut.
    Will this excitement continue onto 2014 and translate into new
    opportunities for China? This panel will explore the state of the capital
    markets in China in comparison to the exciting new developments in the
    U.S. through the prism of biotech insiders, as well as assess the current
    and future attractiveness of local IPOs, providing a global and insightful
    perspective to both companies and investors.

  * China’s Private Health Care Industry
    China has committed to making private healthcare a larger part of the
    overall ecosystem, aiming for 20% of beds and 20% of spending to be
    conducted through private institutions by 2020. This panel will explore
    the opportunities and challenges for private insurers, providers,
    pharmaceutical companies and device manufacturers looking to capitalize on
    the rapidly growth in private healthcare.
  * Early-stage VC funding in China
    While there are still only a few early-stage bio-investors in China, the
    number of funding sources is starting to increase, kick-starting Chinese
    biotech. Where will this diversity of investments take China’s biotech
    industry in the coming years? Hear investors assess the current state of
    early-stage VC funding in China and the long-term outlook for biotech.
  * Case Studies: Partnering Models between Chinese & Western Companies
    Through in-licensing, out-licensing, JV/Alliances and M&A, an increasing
    number of Chinese and Western companies are collaborating to bring
    therapeutics to the market. This session will highlight recent deals from
    2013 to discuss their respective deal structures, what companies need to
    consider to produce the most fruitful partnerships, and where they see
    China and Western collaborations moving in the future.

In addition to panel sessions, BIO China will host company presentations,
partnering meetings and networking opportunities. Keynote speakers will
include:

  * Governor Jay Inslee, Washington State
  * Gary F. Locke, Ambassador of the United States of America to the People’s
    Republic of China
  * Bian Zhenjia, Assistant Minister, CFDA
  * Zhao Yajun, Director General, China Center for Pharmaceutical Exchange
  * James C. Greenwood, President and CEO, Biotechnology Industry Organization

BIO brings to China more than 17 years of experience in organizing
international conferences for the biotech industry, including the BIO
International Convention, the world’s largest annual biotech conference. BIO
is renowned for its successful business development, partnering and investor
meetings in North America, Europe and Asia. Partnering at this conference will
be powered by BIO One-on-One Partnering™, an interactive environment to
intelligently search, contact and schedule private meetings with potential
partners and investors.

For more information on the BIO Convention in China, please visit here.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO members are involved in the research
and development of innovative healthcare, agricultural, industrial and
environmental biotechnology products. BIO also produces the BIO International
Convention, the world’s largest gathering of the biotechnology industry, along
with industry-leading investor and partnering meetings held around the world.
BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling
“innovations transforming our world.” Subscribe to BIOtechNOW.

Upcoming BIO Events

BIO IPCC Conference
November 6-8, 2013
Washington, DC

BIO Convention in China
November 11-13, 2013
Beijing, China

Pacific Rim Summit on Industrial Biotechnology & Bioenergy
December 8-11, 2013
San Diego, CA

BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY

BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan

World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA

BIO International Convention
June 23-26, 2014
San Diego, CA

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

Contact:

Biotechnology Industry Organization
Contact in China:
Amber He, +86 10 8443 9471
amber.he@cohnwolfe.com
or
Contact in U.S.:
Daniel Seaton, 202-962-5207
dseaton@bio.org
or
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement